Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis

BACKGROUND: Understanding the safety and adverse event profiles of PD-1/PD-L1 inhibitors is important in guiding cancer immunotherapy. Consequently, we designed this meta-analysis to evaluate the safety of PD-1/PD-L1 inhibitors in clinical trials involving cancer patients. METHODS: Four safety indic...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Yuan, Huang, Alan, Yang, Yue, Dang, Qi, Wen, Qing, Wang, Linlin, Sun, Yuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184020/
https://www.ncbi.nlm.nih.gov/pubmed/34109117
http://dx.doi.org/10.3389/fonc.2021.662392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184020/
https://www.ncbi.nlm.nih.gov/pubmed/34109117
http://dx.doi.org/10.3389/fonc.2021.662392

Ejemplares similares